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We describe prostate cancer incidence and mortality in Barbados, West Indies. We ascertained all histologically conﬁrmed cases
of prostate cancer during the period July 2002 to December 2008 and reviewed each death registration citing prostate cancer over
a 14-year period commencing January 1995. There were 1101 new cases for an incidence rate of 160.4 (95% Conﬁdence Interval:
151.0–170.2) per 100,000 standardized to the US population. Comparable rates in African-American and White American men
were 248.2 (95% CI: 246.0–250.5) and 158.0 (95% CI: 157.5–158.6) per 100,000, respectively. Prostate cancer mortality rates
in Barbados ranged from 63.2 to 101.6 per 100,000, compared to 51.1 to 78.8 per 100,000 among African Americans. Prostate
cancer risks are lower in Caribbean-origin populations than previously believed, while mortality rates appeared to be higher than
reported in African-American men. Studies in Caribbean populations may assist understanding of disparities among African-
origin populations with shared heredity.
1.Introduction
Prostate cancer rates are higher in westernized African-
origin populations when compared to other ethnic and
racial groups [1, 2]. In the United States, prostate can-
cer remains the principal malignancy in African-American
men and the leading cause of cancer-related death in this
group [3, 4]. Similar ﬁndings have been reported from
the English-speaking Caribbean [5], where the majority
of the population shares a common heredity with African
Americans, as a result of the West African diaspora [6].
Despite the importance of prostate cancer as a cause of ill
health and mortality in the Caribbean, there remains limited
information about disease rates, risk factors, and the clinical
and public health implications for the region [7–10].
The Barbados National Cancer Study (BNCS), funded
by the National Institutes of Health, was established in 2002
to document the incidence and risk factors for prostate
and breast cancer, among the country’s men and women,
respectively. Such malignancies are known to be the most
frequent among the island’s residents [11]. The African-
descent Barbados population shares a common heredity
with African Americans (but with lower admixture) [12],
as well as high rates of lifestyle-related noncommunicable
disease [13–16]. While investigation of conditions relevant
to African Americans in the US may be confounded by
associations with socioeconomic factors, the public care
system in Barbados provides easy access to comprehensive
healthcare at no cost, thus minimizing such concerns. As
demonstrated in our previous work, ﬁndings from the Bar-
badian population may therefore have direct relevance to the
health of African-American populations [17].
In addition to collecting data on prostate cancer inci-
dence, a key outcome of the BNCS, we also utilized the es-
tablished research infrastructure to collect additional infor-
mation on prostate cancer-related mortality. The purpose of
this paper is to present the ﬁrst comprehensive data about
prostate cancer incidence and mortality in Barbados, West
Indies, and provide comparisons with African Americans.
Although African Americans are consistently reported to2 Prostate Cancer
have the highest prostate cancer rates globally, data from
Jamaica [8] suggested that Caribbean men might even have
higher disease rates. This key clinical and public health
concern, underpinned the conduct of this study.
2.Materialsand Methods
All histologically conﬁrmed cases of prostate cancer were
ascertained from records held at the Pathology Department
of the Queen Elizabeth Hospital, Bridgetown, the sole public
tertiary care institution on the island, where all pathological
specimens are evaluated. Other data sources such as patient
charts and pathology reports were also reviewed, and cases
of recurrent prostate cancer or disease occurring in non-
residents (domiciled for less than 6 months a year) were
excluded. Incidence estimates presented here were based on
data collected by the BNCS between 2002 and 2008.
To ascertain prostate cancer-related mortality, we re-
viewed all death certiﬁcates for the period January 1, 1995
to December 31, 2008, selecting certiﬁcates that listed a
diagnosis of prostate cancer alone or in conjunction with
other causes of death. Unlike the requirements of the US
Standard Certiﬁcate of Death, death registration in Barbados
during this period did not require physicians to record un-
derlying cause of death.
To address potential overcounting of deaths attributed to
prostate cancer [18], we developed a nosological algorithm
based on independent review by two clinicians to determine
if prostate cancer was (i) unlikely to be the cause of death,
(ii) the probable cause (multiple causes of death cited, death
likely attributable to metastatic prostate cancer), or (iii) the
deﬁnite cause (prostate cancer being the single listed cause
of death; death attributable to metastatic prostate cancer
with other listed conditions unlikely to have directly caused
death). Two clinicians (A. J. M. Hennis and D. H.-A. Skeete)
resolved any diagnostic discrepancies by consensus.
Informed consent was obtained from all BNCS partici-
pants, and the study protocols conformed to the Declaration
ofHelsinki.In addition,thecurrentstudywasconductedasa
clinicalauditofanationaldatasetonbehalfoftheMinistry of
Health. The data were delinked such that participants could
not be identiﬁed. This study was approved by the University
of the West Indies/Ministry of Health Institutional Review
Board.
2.1. Statistical Methods. To calculate crude prostate cancer
incidence rates per 100,000 years of observation, we divided
the number of incident cases by the number of males (all
ages) in the Barbados population and multiplied the results
by 100,000.Age-speciﬁcincidence rateswere calculatedin 18
age groups (stratiﬁed by 5-year increments as follows: 0–4
years, 5–9 years, 10–14 years, through 85 years, and older).
We derived age-standardized rates (with 95% conﬁdence
intervals),usingthedirectmethod,toallowage-independent
comparisons with other studies. These rates were estimated
based on three standard populations: the 2000 US stan-
dard population [19] and the IARC European and World
standard million populations [20]. We also compared age-
standardized prostate cancer incidence in Barbados (based
on the 2000 US standard population) with US rates (Surveil-
lance Epidemiology and End Results (SEER)) [21], for the
period 2002 to 2007, and calculated age-stratiﬁed and age-
standardized death rates for the period 1995 to 2008. Direct
comparisons of prostate cancer incidence in Barbados and
theUSwere madeutilizingincidencerateratios derivedfrom
log-linear models, according to age and year of diagnosis.
Exact Poisson conﬁdence intervals were calculated for crude
and age-stratiﬁed rates. Given the utility of the Gamma
approximation in providing more accurate estimates with
small numbers, we used this method to estimate age-stand-
ardized conﬁdence intervals [22].
We used previously described approaches to calculate
age-stratiﬁed and age-standardized death rates in Barbados
for the 14-year period 1995–2008. Because of uncertainty
about prostate cancer as an underlying cause of death, we
present two mortality rates, based on (i) deaths restricted
to those deﬁnitely attributed to prostate cancer and (ii)
including all deaths, deﬁnitely or probably attributed to
prostate cancer; deaths unlikely due to prostate cancer were
excluded. US cancer mortality information is provided as
rates only (without documentation of actual numbers), and
stratiﬁed by age groups <65 and 65 years and older. Our
comparisons with US mortality data (presented in Table 5),
are therefore limited by the unavailability of detailed US
data. All analyses were carried out using Stata (Version 11,
StataCorp LP, College Station, Texas, USA).
3.Results
During the initial six and a half year study period (July 1,
2002–December 31, 2008) of the BNCS, 1,101 men were
diagnosed with histologically conﬁrmed prostate cancer.
Table 1 presents age-speciﬁc prostate cancer incidence in
Barbados. Age at presentation ranged from 25 to 99 years,
with a median age of 68 years (interquartile range: 61 to 74
years). Prostate cancer incidence increased from 6.0 (95%
conﬁdence interval: 1.6–15.3) per 100,000 at ages 40 to 44
years, to a peak of 1,026.6 (95% CI: 898.8–1,167.6) per
100,000 in men aged 70 to 74 years, and declined thereafter.
The overall crude incidence rate was 131.0 (95% CI: 123.4–
139.0) per 100,000, with rates of 160.4 (95% CI: 151.0–
170.2), 163.1 (95% CI: 153.4–173.3), and 112.0 (95% CI:
105.2–119.3) per 100,000 standardized to the US, European,
andWorld populations,respectively. Comparablerates inthe
US varied according to race, such that overall prostate cancer
incidence in African-American and White men was 248.2
(95% CI: 246.0–250.5) and 158.0 (95% CI: 157.5–158.6) per
100,000, respectively.
Figure 1 presents age-speciﬁc prostate cancer incidence
in Barbadian men and comparable data from the US. Men
aged 40–44 years comprised the youngest group which
developed prostate cancer and rates were approximately
fourfold higher in African Americans (22.9 (95% CI: 21.1–
24.9)) than Barbadians (6.0 (95% CI: 1.6–15.3); log linear
model comparison, P = .01).Prostate Cancer 3
Table 1: Age-speciﬁc and age-standardized incidence of prostate cancer in Barbados between July 01, 2002 and December 31, 2008, per
100,000 person-years of observation.
Age group (years) Number of cases Person-years∗ Age-speciﬁc rate 95% CI
0–4 0 60,793 0.0 0–6.1
5–9 0 65,446 0.0 0–5.6
10–14 0 65,335 0.0 0–5.7
15–19 0 65,960 0.0 0–5.6
20–24 0 62,648 0.0 0–5.9
25–29 1 68,960 1.5 0–8.1
30–34 0 67,359 0.0 0–5.5
35–39 0 71,536 0.0 0–5.2
40–44 4 66,942 6.0 1.6–15.3
45–49 14 55,952 25.0 13.7–42.0
50–54 79 45,743 172.7 136.7–215.2
55–59 129 30,517 422.7 352.9–502.3
60–64 175 27,778 630.0 540.1–730.6
65–69 203 25,526 795.3 689.6–912.5
70–74 232 22,598 1,026.6 898.8–1,167.6
75–79 147 16,384 897.2 758.0–1,054.5
80–84 74 11,875 623.2 489.3–782.3
85+ 33 9,183 359.4 247.4–504.8
Unknown age 10 — —
Crude rate 1,101 840,535 131.0 123.4–139.0
Age-standardized rates (US) — — 160.4 151.0–170.2
Age-standardized rates (Europe) — — 163.1 153.4–173.3
Age-standardized rates (World) — — 112.0 105.2–119.3
∗85+ age group rounded up to 9,183 to maintain correct person-year total.
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Figure 1: Age-speciﬁc incidence of prostate cancer in Barbados
(2002–2008) and the US SEER 2000–2007 [21]. Note: SEER
incidence rates based on malignantand in situ disease.
The highest prostate cancer incidence among both
Barbadians and African Americans occurred among men
aged 70–74 years: 1,026.6 (95% CI: 898.8–1,167.6) and
1,378.6 (95% CI: 1,347.4–1,410.3) per 100,000, respectively,
stillbeingcomparativelyhigherinthelattergroup(riskratio:
1.34, 95% 1.18–1.53, P<. 001).
Table 2 presentsseculartrendsinincidentprostatecancer
during the period 2002 to 2008. In contrast to an age-
standardized rateof158.8(95%CI:148.6–169.5)per100,000
among Barbadian men, prostate cancer incidence rates
among African Americans always exceeded 225 per 100,000
between 2002 and 2007.
Table 3 presents data on age-speciﬁc and age-standard-
ized prostate cancer incidence in Barbadian and African-
American men. Incidence rate ratios (IRR) conﬁrmed lower
rates ofnewlydiagnosedprostatecancerinBarbadians. Rates
among African Americans were approximately 1.5 times
higher (among men aged 50 to 79) and in excess of 3.5
times higher among the youngest men (aged 40 to 44 years)
(P<. 001 in all age group comparisons from 45 years and
older). Analysis of secular trends in disease incidence during
the 6-year period 2002 to 2007 conﬁrmed overall prostate
cancer incidence to be between 1.3 and 1.9 times higher in
African-American men(P<. 001inallann ualc omparisons).
Table 4 presents age-stratiﬁed and age-standardized
pros-tate cancer death rates in Barbados between 1995 and
2008, per 100,000 person-years of observation. There were a
total of 1,496 death certiﬁcations citing prostate cancer as a
cause of death. Of these, 943 (63.0%) cited prostate canceras
the only cause of death, and 553 (37.0%) cited one or more
other causes. These 553 certiﬁcations with multiple causes
of death were reviewed by two clinicians, and prostate cancer
wasdeterminedtoeitherbetheprobablecauseofdeath(294,4 Prostate Cancer
Table 2: Short-term secular change in prostate cancer incidence in Barbados and in African Americans.
Year Follow-up
months (days)
Cases Person-yrs exposure Age-standardized incidence rate (SEER US 2000 standard population)
Barbados SEER (African Americans; 17
registries)
2002 6 (183) 78 (77) 64,766 146.3 (115.3–183.3) 273.1 (266.3–280.0)
2003 12 (365) 159 (155) 129,177 151.2 (128.3–177.2) 248.3 (241.9–254.8)
2004 12 (366) 195 (192) 129,530 184.1 (158.9–212.3) 245.2 (238.9–251.6)
2005 12 (365) 167 (166) 129,177 159.3 (135.9–185.7) 227.1 (220.9–233.4)
2006 12 (365) 135 (135) 129,177 127.3 (106.7–150.9) 225.8 (220.0–231.7)
2007 12 (365) 188 (187) 129,177 178.2 (153.5–205.9) 227.8 (222.1–233.7)
2008 12 (366) 179 (179) 129,530 169.3 (145.3–196.3) n/a∗
2002–2007 66 (2,009) 922 (912) 711,004 158.8 (148.6–169.5) 248.2 (246.0–250.5)
2002–2008 78 (2,375) 1,101 (1,091) 840,535 160.4 (151.0–170.2) —
SEER rates based on malignant and in situ disease.
∗SEER data for 2008 not available (n/a).
Table 3: Incidence rate ratios (IRRs) comparing age-speciﬁc
incidence rates and secular incidence rates between Barbados and
the United States (SEER 17 registries; African Americans) [6].
Characteristic IRR 95% CI
Age1
40–44 3.84 1.43–10.25
45–49 3.57 2.11–6.05
50–54 1.49 1.20–1.87
55–59 1.39 1.16–1.65
60–64 1.53 1.31–1.77
65–69 1.67 1.46–1.92
70–74 1.34 1.18–1.53
75–79 1.46 1.24–1.72
80–84 1.74 1.38–2.20
85+ 2.45 1.73–3.46
Year2
2002 1.87 1.50–2.34
2003 1.69 1.44–1.98
2004 1.34 1.16–1.55
2005 1.45 1.24–1.69
2006 1.77 1.50–2.11
2007 1.30 1.12–1.50
1Age-speciﬁc incidence rate ratios calculated for ages 40–44 and older—
below age 40 there was just one case of prostate cancer in Barbados.
2Annual incidence rate ratios calculated for ages 40–44 and above using
Poisson regression, adjusted for age. IRRs based on unadjusted crude rates
are (2002) 1.35 (1.08–1.69), (2003) 1.26 (1.07–1.48), (2004) 1.01 (0.88–
1.17), (2005) 1.12 (0.96–1.31), (2006) 1.43 (1.20–1.69), (2007) 1.06 (0.92–
1.23).
19.7% of all deaths) or not likely to be the cause of death
(259, 17.3% of all deaths).
The number of deaths from prostate cancer progressively
increased with age, with the distribution of deﬁnite prostate
cancermortality by10-yearagegroupsbeing1or0.1%(aged
39 orless), 7 or 0.7% (aged 40–49),25 or2.6% (aged 50–54),
25 or 2.6% (aged 55–59), 61 or 6.5% (aged 60–64), 80 or
8.5% (aged 65–69), 132 or 14% (aged 70–74), 173 or 18.3%
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Figure 2: Age-speciﬁc death rates of prostate cancer in Barbados
(1995-2009)(Thebandrepresentingthedistributionofage-speciﬁc
mortality is composed of “deﬁnite” (lower limit) and “deﬁnite and
probable” (upper limit) prostate cancer mortality. ) and the US
SEER 2002–2006.
(80–84), 225 or 24% (aged 85+). Comparable combined
probable and deﬁnite prostate cancer mortality by 10-year
age groups were 1 or 0.1% (aged 39 or less), 7 or 0.6% (40–
49),54or4.4%(50–59),175or14.1%(60–69),396or32.0%
(70–79), 602 or 48.7% (80 years and older). The crude death
rate for deﬁnite prostate cancer deaths was 48.6 (95% CI:
45.5–51.8)per100,000andfordeﬁniteandprobableprostate
cancer deaths, 63.7 (95% CI: 60.2–67.3) per 100,000.
The equivalentage-standardized rates(USstandard 2000
population) were 62.7 (95% CI: 58.8–66.9) deaths per
100,000 person-years for deﬁnite prostate cancer deaths and
82.7 (95% CI: 78.1–87.4) per 100,000 for combined deﬁnite
and probable prostate cancer deaths.
Figure 2 and Table 5 present data comparing mortality
from prostate cancer in the Barbadian and US populations
between 1995 and 2008. In Barbados, overall prostate cancer
mortality (probable and deﬁnite) ranged from 63.2 to 101.6
per 100,000, while overall rates among African AmericansProstate Cancer 5
Table 4: Age-stratiﬁed and age-standardized deﬁnite and probable death rates from prostate cancer in Barbados between Jan 01, 1995 and
Dec 31, 2008, per 100,000 person-years of observation.
Age group
(years)
No. of deﬁnite/(probable
and deﬁnite) prostate
cancer deaths
Person-years
Mortality
Deﬁnite prostate cancer death
(95% CI)
Mortality
Deﬁnite and probable prostate
cancer deaths (95% CI)
0–4 0 140,154 ——
5–9 0 150,870 ——
10–14 0 150,615 ——
15–19 0 152,055 ——
20–24 0 144,420 ——
25–29 0 158,970 ——
30–34 1 155,280 0.6 (0–3.6) 0.6 (0–3.6)
35–39 0 164,910 ——
40–44 0/0 154,320 ——
45–49 7/7 128,985 5.4 (2.2–11.2) 5.4 (2.2–11.2)
50–54 25/26 105,450 23.7 (15.3–35.0) 24.7 (16.1–36.1)
55–59 25/28 70,350 35.5 (23.0–52.5) 39.8 (26.4–57.5)
60–64 61/71 64,035 95.3 (72.9–122.4) 110.9 (86.6–139.9)
65–69 80/104 58,845 136.0 (107.8–169.2) 176.7 (144.4–214.1)
70–74 132/166 52,095 253.4 (212.0–300.5) 318.6 (272.0–371.0)
75–79 173/230 37,770 458.0 (392.3–531.6) 608.9 (532.8–692.9)
80–84 212/276 27,375 774.4 (673.7–866.0) 1,008.2 (892.8–1,134.5)
85+ 225/326 21,165 1,063.1 (928.7–1,211.4) 1,540.3 (1,377.6–1,716.9)
Age unknown 2/2 — —
Total 943/1,237 1,937,664
Crude rate 48.6 (45.5–51.8) 63.7 (60.2–67.3)
Age-standardized rates
(US) — — 62.7 (58.8–66.9) 82.7 (78.1–87.4)
Age-standardized rates
(Europe) — — 49.6 (46.4–53.0) 64.3 (60.7–68.2)
Age-standardized rates
(World) — — 29.7 (27.7–31.9) 38.1 (35.8–40.6)
ranged from 51.1 to 78.8 per 100,000. During the period
1995 to 1998, overall rates of “deﬁnite” prostate cancer
mortality in Barbados were lower than reported in African
Americans (52.3–67.7 and 72.8–78.3 per 100,000, resp.).
In contrast, mortality rates in Barbados due to deﬁnite
prostate cancer between 1999 and 2006 (barring the year
2001)wereconsistentlyhigherthanthosereportedinAfrican
Americans, who demonstrated a trend to declining related
mortality. With regards to age-stratiﬁed, Barbadian men
aged less than 65 years had higher mortality attributed
to deﬁnite prostate cancer than African Americans (except
for 1998 and 2003). Among men aged 65 years and older,
death rates attributable to probable and deﬁnite prostate
cancer were higher among older Barbadian men between
1998 and 2006. Figure 2 compares age-speciﬁc prostate
cancer mortality, rates in White and African Americans,
with Barbadians. Based on “deﬁnite” prostate cancer-related
deaths, age-speciﬁc mortality rates in Barbados were at least
as high as those in African Americans for all age groups and
higher when prostate cancer was considered the combined
“deﬁnite and probable” cause of death. Mortality increased
with older age in each of the three ethnic groups.
4.Discussion
A total of 1101 incident prostate cancer cases were recorded
in Barbados during the six and a half year study period
(July 2002 to December 2008), for an incidence rate of
160.4 per 100,000 (standardized to the US population).
This prostate cancer incidence was similar in Barbadian
and White American men, in contrast to rates in African-
American men, which were about one and a half times
higher. The age-speciﬁc pattern of incident disease was simi-
lar in both African-descent groups, rising to a peak by ages
70 to 74 years, and declining thereafter. Younger African-
American men aged 40 to 44 years, however, experienced
a nearly fourfold higher occurrence of prostate cancer than
similarly aged Barbadian men (groups based on relatively
low numbers). While overall prostate cancer mortality rates6 Prostate Cancer
Table 5: Annual age-standardized deﬁnite and probable death rates from prostate cancer in Barbados compared to US SEER data (African
Americans) between Jan 01, 1995 and Dec 31, 2009, per 100,000 person-years of observation.
Prostate cancer death rates
Year Barbados1 SEER (African Americans)
All <65 years 65+ years All <65 years 65+ years
1995 67.7/82.9 6.7/7.9 489.5/602.0 78.2 6.7 572.5
1996 52.3/63.2 7.6/8.6 361.2/440.4 78.8 6.5 579.2
1997 66.8/72.7 10.8/10.8 453.6/500.4 74.3 6.3 544.2
1998 61.4/74.8 4.2/4.2 457.1/562.9 72.8 6.3 532.4
1999 72.5/84.7 8.5/8.5 514.3/611.1 70.1 5.8 514.8
2000 70.5/86.2 9.5/10.6 491.9/609.4 68.7 5.4 505.8
2001 60.5/81.4 10.1/13.3 408.3/552.4 66.5 5.4 488.9
2002 78.7/88.8 10.8/10.8 548.4/628.2 63.0 5.4 461.2
2003 63.7/84.5 3.2/5.2 481.8/632.3 58.0 5.4 421.4
2004 63.4/85.4 6.2/7.4 458.7/625.4 56.2 5.0 410.4
2005 64.7/92.7 8.4/8.4 454.0/675.0 54.2 5.0 393.8
2006 53.2/75.4 11.5/13.7 341.4/501.8 51.1 4.8 371.0
2007 50.8/74.0 12.6/13.6 315.4/491.3 n/a2 n/a2 n/a2
2008 61.9/101.6 8.8/10.9 428.9/728.2 n/a2 n/a2 n/a2
2009 52.8/91.4 7.2/7.2 368.3/673.3 n/a2 n/a2 n/a2
1All death certiﬁcateshave been independentlyreviewed by two clinicians.We report two rates, where prostate cancer has been classiﬁedas a deﬁnite cause of
death/and combined deﬁnite or probable cause of death.
2Mortality data for 2007 to 2009 not available (n/a).
demonstrated a clear decline in African Americans during
the period from 2000 to 2006, they were higher in Barbadian
men.
Prostate cancer ranks as the sixth most frequent incident
tumorworldwide, accountingfornearly10%ofallcancersin
men [23]. Prevalence is higher in developed than developing
countries, where 15% and 4% of men are aﬀected, respec-
tively.
There are clear associations between prostate cancer
occurrence and race (or ethnicity) such that African-
American men experience the highest rates globally, Cau-
casian men in North America and Europe, high and inter-
mediate rates, while Asian men have relatively low disease
rates [1, 23, 24]. Based oncomprehensive global population-
based cancer data reported continuously over a 20-year
period by the International Agency for Research in Cancer
(IARC), the highest prostate cancer incidence and mortality
worldwide was documented in African-American men [1].
Incidenceand mortality ratesin African-American men were
approximately sixty times and twelve times, respectively,
t h o s er e c o r d e di nC h i n e s em e n( k n o w nt ob ea tl o w e s tr i s k ) .
Few data exist on prostate cancer rates in West African
and Caribbean populations who share a common heredity
with African-American populations. Much of the currently
available data have been reported from the Globocan
database, often the only source of cancer data from many
regions of the world [5]. It is important to note that the
authors caution that the “degree of detail and quality of
the data vary considerably” and provide the caveat that the
quality of information presented depends “on the extent
and accuracy of locally available data.” While there are
extensive data on prostate cancer rates among African-
American populations, few data are available for West
African populations, who are thought to have relatively high
disease rates [25].
Prostate cancer is listed as the second most frequent
malignancy among West African men with rates of approx-
imately 19 per 100,000 [26]. Two independent hospital-
based studies conducted in Nigeria reported prostate cancer
incidence rates of 61.3 per 100,000 and 127 per 100,000
[27, 28] .H o w e v e r ,ac r i t i c a lr e a p p r a i s a lb yB e n - S h l o m oe ta l .
highlighted major errors in these estimates [29]. Their
revised calculations reduced these estimated incident rates
to 6.1 per 100,000 and 21.1 per 100,000, respectively. Ben-
Shlomo et al. similarly recalculated prostate cancer inci-
dence reported in a hospital-based case series conducted in
Cameroon at 0.2 per 100,000 [29], rather than the reported
rate of 93.8 per 100,000 [30]. These hospital-based studies
conducted in the 1980s to mid 1990s would have led to
erroneous estimates of cancer incidence and reevaluation of
thesedataprovidesevidenceforrelativelylowprostatecancer
rates in West Africa.
Further evidence of relatively low prostate cancer inci-
dence rates in West Africa comes from cancer registry data
from Guinea (8.1 per 100,000), Mali (6.3 per 100,000), and
Gambia (1.2 per 100,000) a decade and a half ago [31, 32].
Information is now available from studies of ﬁrst gen-
eration Black Caribbean and African men resident in the
United Kingdom. Risk of incident prostate cancer was three
times higher in African Caribbean compared to European
men resident in North East London [33]. The larger Prostate
Cancer in Ethnic Subgroups (PROCESS) study of incidentProstate Cancer 7
prostate cancer conducted in London and Bristol over a
longer (5-year) period documented adjusted rates (based
on the European standard population) of 173.1 per 100,000
for Black Caribbean men and 139.3 per 100,000 for Black
African men, compared to 56.4 per 100,000 in White British
men [29]. Standardized to the US population, prostate
cancer incidence was 166 per 100,000 among Black British
men, inline with the rate of 158.9 per 100,000 among
Barbadian men.
4.1. Prostate Cancer Incidence in the Caribbean. The com-
paratively lower rates of prostate cancer in Barbadian men
contrasts with earlier reports from Jamaica, West Indies,
where the reported average incidence rate of 304 per 100,000
(1989 to 1994) exceeded comparable rates in African-
American men (249 per 100,000) [8]. The accuracy of the
Jamaican rates has also been challenged by Ben-Shlomo et
al., who estimated the corrected prostate cancer incidence
(unadjusted) to be less than one-fourth the original rate at
70 per 100,000 [29]. They suggested that standardization of
these rates to the US population would reduce this estimate
even further, given the comparably younger average age of
the Jamaican population. Based on data from the largely
urban-based Jamaica Cancer Registry, Hanchard et al. [7]
and Gibson et al. [10] reported standardized prostate cancer
incidence rates (world population) of 56.4 and 65.6 per
100,000, respectively, over consecutive 4-year periods, (1993
to 1997 and 1998 to 2002). These rates are entirely consistent
with those estimated by Ben-Shlomo et al. [29].
Limited data on prostate cancer incidence are available
from theFrench Caribbeanislands, which also have predom-
inantly West African-origin populations. There has been an
active cancer registry in Martinique since 1983, and Dieye
et al. [34] reported a cumulative age-standardized (world
population) prostate cancer incidence of 80.8 per 100,000
(between 1981 and 2000). Annual rates increased over time
to 161 per 100,000 in 2000, comparable to rates in Barbados.
Prostate cancer incidence was also similar in Guadeloupe at
a rate of 168 per 100,000 [35]. Based on registry reports,
prostate cancer rates (standardized to the world population)
were relatively lower in Cuba (Hispanic Caribbean: 34.9 per
100,000 in 1999) [36].
In sum, prostate cancer incidence is similar in Black
Caribbean populations resident in the United Kingdom and
FrenchandBarbadianpopulationsresidentintheCaribbean,
and is around the order of 160 per 100,000. This is in sharp
contrast to earlier reported incidencerates ofaround 300 per
100,000 from Jamaica, which appear to be an overestimate.
Our ﬁndings, supported by other reports, therefore indicate
thattheimpression oftheCaribbeanbeinga high-risk region
for prostate cancer is incorrect.
The impact of screening must be speciﬁcally addressed,
as it signiﬁcantly inﬂuences prostate cancer incidence.
Increased utilization of prostate-speciﬁc antigen (PSA)
screening and higher uptake of transurethral prostatic resec-
tion signiﬁcantly contributed to increased prostate cancer
rates in the US [37–39]. Anecdotally, PSA screening in the
Caribbean region still lags behind uptake in more developed
regions. Bunker et al. reported a prevalence of 10% for
screen-detected prostate cancer in Tobago, West Indies [9],
which highlights the potential impact ofincreased utilization
of screening on disease rates.
4.2. Prostate Cancer Mortality. Cancer is now the second
leading cause of death in the US accounting for 1 in 4
deaths [40, 41]. Racial disparities in cancer mortality persist
in the US, although survival has improved in virtually all
ethnic groups [3]. As such, survival after a cancer diagnosis
still remains poorer among Black than White Americans
[42]. Prostate cancer mortality has been approximately two
times higher among Black than White Americans in recent
decades [43], and current global comparisons conﬁrm worse
mortality outcomes in African-American men [24]. Vital
statistics from the UK indicate that prostate cancer mortality
rates among men born in West Africa and the West Indies
are two to three times higher than overall rates in the
male population [2]. Limited data also conﬁrm lower 5-year
survival among Black than White men following a prostate
cancer diagnosis [44].
Factors expected to aﬀect outcomes, such as preexisting
comorbid conditions and access to care or uptake of PSA
screening, did not emerge as independent predictors of eth-
nic disparities in prostate cancer mortality in a recent meta-
analysis [45]. These ﬁndings must, however, be viewed with
caution, given the substantial body of information to the
contrary [46–48]. Tumor grade (biological aggressiveness)
[49], underpinned by speciﬁc genetic diﬀerences [50], may
partly explain racial disparities in prostate cancer mortality.
Mortality rates following a prostate cancer diagnosis in
recent years are at least similar, in Barbadian and African-
American men (and to some extent higher in the former
group). This ﬁnding is a cause for concern, given the com-
paratively lower prostate cancer incidence in Barbados.
A unique strength of this study concerns the access to
all histologic samples analyzed at the island’s sole pathology
department, leading to near complete ascertainment of all
incident prostate cancer cases. The strict criteria we used
to establish a diagnosis of prostate cancer, which required
histological conﬁrmation, would have however reduced
the true number of cases, as standard practice includes
observation or empiric treatment of elderly men without
proceeding to biopsy. This practice would have resulted
in an underestimate of prostate cancer incidence in this
study. While information about the uptake of biopsy in
the diagnosis of prostate cancer nationally would have been
useful, this was beyond the scope of this study. It is also
our view that there is a lower uptake of PSA screening in
Barbados compared to the US, which coupled with lower
biopsy rates would have also led to an underestimate of
prostate cancer incidence. The majority of the Barbadian
population is of African descent, with fewer than 5% of men
self-reporting White race (2000 household census). This low
percentage of non-African descent Barbadians is likely to
have minimal eﬀect on our prostate cancer rates and allows
comparison with other similar populations.8 Prostate Cancer
A potential limitation is that diﬀerences in death cer-
tiﬁcation processes would have aﬀected the comparability
of prostate cancer mortality rates in Barbados versus the
United States. We therefore developed an algorithm to clas-
sify prostate cancer-related deaths. This algorithm used an
extremely conservative approach, with death only attributed
to prostate cancer, where it was listed as the only cause,
or the death certiﬁcates provided clear evidence of death
due to metastatic prostate cancer. This methodology would
have likely led to underestimates of prostate cancer as a
“deﬁnite” cause of mortality and reduced related mortality
rates accordingly. This research was based on comprehensive
access to information that allowed identiﬁcation, for the
ﬁrst time, of all incident prostate cancer cases and deaths
occurring on the island, although the caveats noted would
have to be considered in the interpretation of our ﬁndings.
5.Conclusions
This paper describes the incidence and mortality from
prostate cancer in Barbados, West Indies, mainly populated
by individuals of West African descent. Incidence rates were
found to be consistent with those of similar populations
in the Caribbean, as well as Caribbean populations in the
United Kingdom, and lower than rates reported in African
Americans. In spite of easy access to comprehensive health
care, freely available in the public sector, prostate cancer
mortality was comparatively higher than rates experienced
by African-American populations. This observation calls for
clinicaland publichealthapproachestoimprovedetectionof
disease, in order to reduce the high mortality rates currently
experienced.
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